Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

OP-2000 granted new generic name by USAN

Jan. 24, 2002

P&G assumes marketing of Asacol in the U.K.

Jan. 22, 2002

Cholecystokin and gastrin receptor ligands in development at James Black Foundation

Jan. 17, 2002

Antisense oligodeoxynucleotide targeting Bid inhibits bile acid-induced liver injury

Jan. 17, 2002

Hepatitis B vaccine candidate selected in Genencor/Epimmune collaboration

Jan. 16, 2002

Rosiglitazone as a novel therapy for ulcerative colitis

Jan. 16, 2002

Encouraging phase Ia results of XTL-002 in hepatitis C

Jan. 15, 2002

First human trial yields positive data on L-dT, a potential new therapy for HBV

Jan. 11, 2002

Gastric and cholecystokinin receptor ligands claimed in patents by James Black researchers

Jan. 10, 2002

Cell adhesion inhibitor IS-741 effective in rat model of IBD

Jan. 10, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...